Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 4 SPEC.ISS., 2004, Pages 573-584

  Foss, Francine M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Antimetabolites; Myelodysplastic syndrome; Nucleoside analogs

Indexed keywords

ANTIMETABOLITE; ARSENIC TRIOXIDE; BEVACIZUMAB; CLADRIBINE; CYTARABINE; DEOXYADENOSINE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IDARUBICIN; INTERLEUKIN 3; MATRIX METALLOPROTEINASE INHIBITOR; MELPHALAN; NUCLEOSIDE ANALOG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RUBITECAN; TEZACITABINE; THALIDOMIDE; TIOGUANINE; TOPOTECAN; TROXACITABINE; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANGIOGENESIS; BONE MARROW; BONE MARROW HYPOPLASIA; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOGENETICS; DRUG FATALITY; ELDERLY CARE; HEMATOPOIESIS; HUMAN; MALIGNANT TRANSFORMATION; META ANALYSIS; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; SYSTEMATIC REVIEW;

EID: 5744221187     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.009     Document Type: Review

References (64)

1. A. Ganser D. Hoelzer Clinical course of myelodysplastic syndromes Hematology/Oncology Clinics of North America 6 1992 607-618
2. J.E. Anderson Bone marrow transplantation for myelodysplasia Blood Reviews 14 2000 63-77
3. J.M. Bennett D. Catovsky M.T. Daniel et al. Proposals for the classification of the myelodysplastic syndromes British Journal of Haematology 51 1982 189-199
4. P. Greenberg C. Cox M.M. LeBeau et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079-2088
5. Anonymous NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network. Oncology (Huntingt)., 1998;12:53-80
6. C.M. Galmarini J.R. Mackey C. Dumontet Nucleoside analogues: mechanisms of drug resistance and reversal strategies Leukemia 15 2001 875-890
7. J.L. Grem C.H. Takimoto P. Multani et al. Antimetabolites Cancer Chemotherapy and Biological Response Modifiers 18 1999 1-38
8. S.A. Johnson Nucleoside analogues in the treatment of haematological malignancies Expert Opinion Pharmacotherapy 2 2001 929-943
9. B.D. Cheson D.M. Jasperse R. Simon M.A. Friedman A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes Journal of Clinical Oncology 4 1986 1857-1864
10. C. Aul N. Gattermann The role of low-dose chemotherapy in myelodysplastic syndromes Leukemia Research 16 1992 207-215
11. C. Aul W. Schneider The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes Cancer 64 1989 1812-1818
12. K.B. Miller K. Kim F.S. Morrison et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study Annals of Hematology 65 1992 162-168
13. S. Kuriya K. Murai Y. Miyairi et al. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study Cancer 78 1996 422-426
14. N.C. Munshi G.J. Tricot Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia Annals of Hematology 74 1997 111-115
15. H.H. Gerhartz R. Marcus A. Delmer et al. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group Leukemia 8 1994 16-23
16. E.P. Alessandrino S. Amadori G. Barosi et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology Haematologica 87 2002 1286-1306
17. H.A. Rossi J. O'Donnell F. Sarcinelli et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome Leukemia 16 2002 310-315
18. H.D. Preisler A. Raza M. Barcos et al. High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study American Journal of Hematology 23 1986 131-134
19. T. De Witte S. Suciu M. Peetermans et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG) Leukemia 9 1995 1805-1811
20. M. Beran Y. Shen H. Kantarjian et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens Cancer 92 2001 1999-2015
21. F. Guilhot R. Bouabdallah B. Desablens et al. Topotecan, cytosine arabinoside and G-SCF (TAG) versus idarubicin, cytosine arabinoside and G-CSF (IDAG) in patients with myelodysplastic syndromes (MDS) or MDS in transformation: a randomized phase III study Blood 100 2002 98a (abstr.)
22. E. Berman G. Heller J. Santorsa et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 77 1991 1666-1674
23. T. De Witte P. Muus B. De Pauw C. Haanen Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia Cancer 66 1990 831-837
24. E. Wattel S. De Botton L.J. Luc et al. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders British Journal of Haematology 98 1997 983-991
25. A.F. List C.M. Spier A. Cline et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype British Journal of Haematology 78 1991 28-34
26. E. Estey P. Thall M. Beran Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy Blood 90 1997 2969-2977
27. S.H. Bernstein V.L. Brunetto F.R. Davey et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study Journal of Clinical Oncology 14 1996 2486-2494
28. P. Fenaux P. Morel C. Rose et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy British Journal of Haematology 77 1991 497-501
29. W.J. Hirst G.J. Mufti The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes Leukemia Research 18 1994 797-804
30. J. Cortes H. Kantarjian M. Albitar et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome Cancer 97 2003 1234-1241
31. V. Gandhi E. Estey M.J. Keating W. Plunkett Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy Journal of Clinical Oncology 11 1993 116-124
32. J.E. Parker A. Pagliuca A. Mijovic et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia British Journal of Haematology 99 1997 939-944
33. A. Tsimberidou J. Cortes D. Thomas et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia Leukemia Research 27 2003 893-897
34. G. Ossenkoppele W. Graveland P. Sonneveld et al. Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML Blood 100 2002 792a (abstr.)
35. B.D. Cheson D.A. Vena F.M. Foss J.M. Sorensen Neurotoxicity of purine analogs: a review Journal of Clinical Oncology 12 1994 2216-2228
36. A.D. Mario L. Pagano L. Mele et al. Use of gemcitabine (GEM) in advanced myelodysplastic syndromes Annals of Oncology 2001 12
37. X. Zhou C.U. Meyer P. Schmidtke F. Zepp Effect of cordycepin on interleukin-10 production of human peripheral blood mononuclear cells European Journal of Pharmacology 453 2002 309-317
38. F.M. Foss Combination therapy with purine nucleoside analogs Oncology (Huntingt) 14 2000 31-35
39. F.J. Giles G. Garcia-Manero J.E. Cortes et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia Journal of Clinical Oncology 20 2002 656-664
40. F.J. Giles S. Faderl D.A. Thomas et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias Journal of Clinical Oncology 21 2003 1050-1056
41. S. Faderl G. Garcia-Manero D. Thomas Phase I study of tezacitabine (FMdC) in patients with relapsed and refractory hematologic malignancies Blood 98 2001 595a (abstr.)
42. S. Faderl V. Gandhi H. Kantarjian W. Plunkett New nucleoside analogues in clinical development Cancer Chemotherapy and Biological Response Modifiers 20 2002 37-58
43. H.M. Kantarjian V. Gandhi J. Cortes et al. Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemia Blood 2003
44. S.A. Streltsov Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I Journal of Biomolecular Structure and Dynamics 20 2002 447-454
45. F. Leteurtre G. Kohlhagen M.R. Fesen et al. Effects of DNA methylation on topoisomerase I and II cleavage activities The Journal of Biological Chemistry 269 1994 7893-7900
46. M. Lopez-Baena S. Mateos J. Pinero et al. Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine Mutation Research 421 1998 109-116
47. M. Beran H. Kantarjian S. O'Brien et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 88 1996 2473-2479
48. M. Beran E. Estey S.M. O'Brien et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia Leukemia and Lymphoma 31 1998 521-531
49. M. Beran E. Estey S. O'Brien et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia Journal of Clinical Oncology 17 1999 2819-2830
50. J. Cortes A.M. Tsimberidou R. Alvarez et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia Cancer Chemotherapy and Pharmacology 50 2002 497-500
51. D.L. Grinblatt Y. Daohai V. Hars et al. Relationship response to oral topotecan for myelodysplastic syndrome (MDS) with IPSS group and cytogenetics-A CALGB study 19803 Blood 100 2002 794a (abstr.)
52. J. Cortes S. O'Brien M. Beran et al. Efficacy of a topoisomerase I inhibitor, 9-nitro-20-(S)-camptothecin (9-NC, RFS2000) in chronic myelomonocytic leukemia (CMML) and high-risk myelodysplastic syndromes Blood 98 2001 621a (abstr.)
53. V. Ribrag F. Suzan C. Ravoet et al. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts Leukemia 17 2003 319-322
54. F.J. Giles J.E. Cortes D.A. Thomas et al. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia Clinical Cancer Research 8 2002 2134-2141
55. E. Apostolidou G. Garcia-Manero J. Cortes et al. Phase I study of OSI-211, a novel liposomal topoisomerase 1 (Topo 1) inhibitor, in patients with refractory leukemia Blood 100 11 2002 262b
56. Apostolidou E, Garcia-Manero G, Cortes J et al. Phase I study of OSI-211, a novel liposomal topoisomerase 1 (Topo 1) inhibitor, in patients with refractory leukemia. Blood 2002; 100: 262b
57. A. Argiris P. Heald T. Kuzel et al. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma Investigational New Drugs 19 2001 321-326
58. E. Omoto S. Deguchi S. Takaba et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes Leukemia 10 1996 609-614
59. C. Denzlinger D. Bowen D. Benz et al. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia British Journal of Haematology 108 2000 93-95
60. D.T. Bowen K. Gelly M. Groves The evolving ethical dilemma of low dose melphalan chemotherapy in advanced MDS/AML: quality of life in remission versus predictable induction of 17p deletion Leukemia Research 25 2001 S65
61. E.J. Feldman K.P. Seiter T. Ahmed et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia Leukemia 10 1996 40-42
62. H.H. Gerhartz H.H. Zwierzina J. Walther et al. Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group Cancer Investigation 14 1996 299-306
63. T. Ruutu A. Hanninen G. Jarventie et al. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine Leukemia Research 21 1997 133-138
64. E.H. Estey P.F. Thall S. Pierce et al. Randomized phase II study of fludarabine+cytosine arabinoside+idarubicin+/- all-trans retinoic acid+/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome Blood 93 1999 2478-2484